Open AccessExpression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.
Author(s) -
Tomokazu Aoki,
Kei Tashiro,
ShinIchi Miyatake,
Tatsuo Kinashi,
Toru Nakano,
Yoshifumi Oda,
Hiroe Kikuchi,
Tasuku Honjo
Publication year - 1992
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.89.9.3850
Subject(s) - glioma , fibrosarcoma , transfection , biology , cd8 , in vivo , cell culture , immune system , cancer research , microbiology and biotechnology , secretion , immunology , endocrinology , genetics
We have examined the immunoregulatory effect of local and continuous secretion of interleukin 7 (IL-7) from murine glioma cells (203-glioma) engineered by murine IL-7 gene transfection. Secretion of IL-7 from glioma cells did not result in morphology or growth rate changes but did reduce tumorigenicity in vivo in proportion to the amount of IL-7 produced. This reduction in tumorigenicity could be reversed in a dose-dependent fashion by injection of anti-IL-7 neutralizing monoclonal antibody at the tumor site. Mice immunized with IL-7-producing glioma cells showed a specific immune response to 203-glioma but not to two other syngeneic cell lines (B-16, a melanoma, and YM-12, a fibrosarcoma). IL-7-producing glioma cells were not rejected in mice depleted of CD8+ cells but were rejected in mice depleted of CD4+ or NK1.1+ cells. These results suggest that CD8+ T cells may play an important role in tumor rejection.